Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  degarelix
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0993, NCI-2013-00460, NCT01786265
Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB#13-000714, NCI-2015-01448, EMT13001, NCI-2014-02414, NCT01990196
Ipilimumab and Degarelix with or without Surgery in Treating Patients with Newly Diagnosed Metastatic or Recurrent Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-134, NCI-2013-02489, BMS CA 184 237, NCT02020070
Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 14-0909, NCI-2014-02219, NCT02278185
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
Degarelix before Surgery in Treating Patients with Intermediate or High-Risk Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-182, NCI-2012-00230, NCT01542021
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7846, NCI-2012-02136, NCT01731912
Start Over